Showing results (31-40 of 42) with videos related to
Sort By:
Pageof 5
Frontiers in Pharmacology|November 13, 2018
Identification and Characterization of Novel CFTR PotentiatorsMaarten Gees, Sara Musch, Steven Van der Plas, et al.Journal of Medicinal Chemistry|January 5, 2021
Discovery of GLPG2451, a Novel Once Daily Potentiator for the Treatment of Cystic FibrosisSteven E Van der Plas, Hans Kelgtermans, Oscar Mammoliti, et al.Journal of Immunology (Baltimore, Md. : 1950)|September 6, 2013
Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseasesLuc Van Rompaey, René Galien, Ellen M van der Aar, et al.The Journal of Pharmacology and Experimental Therapeutics|November 17, 2019
Biological Characterization of F508delCFTR Protein Processing by the CFTR Corrector ABBV-2222/GLPG2222Ashvani K Singh, Yihong Fan, Corina Balut, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 7, 2019
CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trialsScott C Bell, Peter J Barry, Kris De Boeck, et al.The European Respiratory Journal|December 17, 2021
Evaluation of a novel CFTR potentiator in COPD ferrets with acquired CFTR dysfunctionNiroop Kaza, Vivian Y Lin, Denise Stanford, et al.Antimicrobial Agents and Chemotherapy|July 31, 2013
A novel, broad-spectrum inhibitor of enterovirus replication that targets host cell factor phosphatidylinositol 4-kinase IIIβHilde M van der Schaar, Pieter Leyssen, Hendrik J Thibaut, et al.Journal of Medicinal Chemistry|November 18, 2017
Discovery of N-(3-Carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-lH-pyrazole-5-carboxamide (GLPG1837), a Novel Potentiator Which Can Open Class III Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channels to a High ExtentSteven E Van der Plas, Hans Kelgtermans, Tom De Munck, et al.Journal of Medicinal Chemistry|March 25, 2024
Discovery of GLPG2737, a Potent Type 2 Corrector of CFTR for the Treatment of Cystic Fibrosis in Combination with a Potentiator and a Type 1 Co-correctorMathieu Pizzonero, Rhalid Akkari, Xavier Bock, et al.Journal of Medicinal Chemistry|September 9, 2020
Discovery of 9-Cyclopropylethynyl-2-((S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical TrialFrédéric Labéguère, Sonia Dupont, Luke Alvey, et al.Pageof 5